Introduction:
Epidermolysis bullosa (EB) is a heterogeneous group of rare hereditary blistering disorders with an incidence of ۱.۴–۲۵.۰ per million live births and a prevalence of ۲.۸۲–۵۴.۰ per million population [۱]. The most recent classification of EB includes four major classical forms, EB simplex (EBS), junctional EB (JEB), dystrophic EB (DEB), Kindler EB (KEB), and several other skin fragility disorders under its term of EB [۲]. Most forms of EB result from recessive or dominant mutations in genes encoding structural proteins at or near the dermal-epidermal junction (DEJ). Sixteen genes contribute to the classic EB genetic pathology, and an additional ۲۴ genes add to the full list of candidate genes in the broader classification of EB. Clinically, some forms of EB such as localized EBS give only a few seasonal blisters that may be confined to the toes. In contrast, other forms of EB can produce more extensive blisters and often involve various mucous membranes and noncutaneous lesions such as muscles, gastrointestinal tract, lungs, and kidneys [۳]. This diversity of clinicopathology poses great challenges to optimizing patient management. To date, most treatments have focused on improving wound healing and treating patient symptoms such as itching and pain. However, there is no cure for EB and there is a significant unmet need to improve clinical care and quality of life for patients. In recent years, attempts have been made to develop gene, cell, and protein therapies aimed at correcting the underlying primary genetic pathology in various forms of EB. Cell-based therapies use primary cells, blood cells, stem cells, stromal cells, progenitor cells, or iPSCs alone or in combination with preconditioning, fractionation, or genetic modification [۴, ۵].Materials and Methods: This study aimed to explore the latest developments in cell-based therapies for EB. Therefore, Science Direct, PubMed, and Scopus databases were explored and related original articles and clinical trial studies were investigated with the keywords Epidermolysis bullosa, cell therapy, and wound healing.Results: In EB, cell therapy, including keratinocytes, fibroblasts, bone marrow transplantation (BMT), stem/stromal cells (MSCs), and iPSCs, was evaluated in several trials. initial clinical trial. It includes autologous, allogeneic, or autologous donors. Keratinocytes: According to the technical feasibility of human keratinocyte cultures in ۱۹۷۵ [۶], autologous keratinocytes from